Implantable Cardioverter Defibrillators Market Analysis
The market by product is segmented into transvenous implantable cardioverter-defibrillators and subcutaneous implantable cardioverter defibrillators. The transvenous ICD segment accounted for majority revenue share and was valued at around USD 6.8 billion revenue in 2023.
- Transvenous ICDs have a well-established track record of clinical efficacy in treating life-threatening ventricular arrhythmias. Their effectiveness in quickly and accurately detecting abnormal heart rhythms and delivering timely defibrillation shocks has contributed to their widespread adoption.
- Moreover, it has broad arrhythmia detection capabilities, enabling for the identification and treatment of various ventricular arrhythmias. This feature is essential in the management of individuals who are at risk of sudden cardiac death owing to a variety of cardiac diseases, thereby improving overall efficiency.
Based on type, the market is categorized into single-chamber ICDs, dual-chamber ICDs, and biventricular devices. The biventricular devices segment dominated the implantable cardioverter defibrillators market and accounted for over 42% market share in 2023 and is anticipated to witness significant growth during the forecast period.
- Biventricular devices are primarily indicated for patients with heart failure and conduction abnormalities. The devices improve the coordination of the heart's contractions, enhancing overall cardiac function and reducing symptoms associated with heart failure.
- Additionally, it integrate cardiac resynchronization therapy with defibrillation capabilities. This combination addresses both the synchronization issues in heart failure patients and provides protection against life-threatening ventricular arrhythmias, offering comprehensive treatment in a single device, leading to the segmental growth.
The implantable cardioverter defibrillators industry by end-use is categorized into hospitals, ambulatory surgical centers, and other end-users. The hospitals segment accounted for over USD 4.5 billion revenue in 2023.
- Hospitals are witnessing a demand for ICDs due to several factors, reflecting both clinical needs and technological advancements. Favorable reimbursement policies for ICD implantation and related procedures encourage healthcare providers to offer these devices to eligible patients.
- Furthermore, hospitals strive to offer comprehensive cardiac care services to meet the diverse needs of their patient populations. Incorporating ICDs into their service offerings allows hospitals to provide a full spectrum of advanced cardiac therapies, enhancing their reputation as leading healthcare institutions.
North America implantable cardioverter defibrillators market accounted for USD 4.7 billion revenue in 2023 and is predicted to witness substantial market growth over the analysis timeline.
- The region is at the forefront of technological innovation in healthcare sector. Ongoing advancements in ICDs, such as miniaturization, longer battery life, and improved lead designs, contribute to the adoption of state-of-the-art devices in the region.
- Furthermore, North America boasts a robust healthcare infrastructure with advanced medical facilities and a high level of accessibility to healthcare services. This infrastructure supports the widespread adoption of ICDs across various healthcare settings, including hospitals and specialized cardiac care centers.